Manufacturer
Menarini - Von Heyden GmbH
Contents
Ranolazine
Indication
Add-on therapy for symptomatic treatment of patients w/ stable angina pectoris who are inadequately controlled or intolerant to 1st-line antianginal therapies (eg, β-blockers &/or Ca antagonists).
Instruction
May be taken with or without food: Swallow whole, do not break/chew/crush.
Drug interaction
Increased plasma conc w/ CYP3A4 inhibitors (eg, itraconazole, ketoconazole, voriconazole, posaconazole, HIV PIs, clarithromycin, telithromycin, nefazodone, grapefruit juice; diltiazem, erythromycin, fluconazole), P-gp inhibitors (eg, ciclosporin, verapamil) & CYP2D6 inhibitors (eg, paroxetine). Decreased steady state conc w/ CYP3A4 inducers (eg, rifampicin, phenytoin, phenobarb, carbamazepine, St. John's wort). Increased plasma conc of P-gp or CYP3A4 substrates (eg, simvastatin, lovastatin, atorvastatin; ciclosporin, tacrolimus, sirolimus, everolimus), other CYP2D6 substrates (eg, propafenone & flecainide, TCAs & antipsychotics), metoprolol, digoxin. Increased plasma exposure of metformin & other OCT2 substrates (eg, pindolol & varenicline). Theoretical risk of increased possible risk of ventricular arrhythmias w/ other drugs known to prolong QTc interval eg, certain antihistamines (eg, terfenadine, astemizole, mizolastine), antiarrhythmics (eg, quinidine, disopyramide, procainamide), erythromycin & TCAs (eg, imipramine, doxepin, amitriptyline).
Malaysia
